Vincristine Sulfate
2068-78-2CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)OAQTQHPDCURKLKT-JKDPCDLQSA-NVincristine Sulfate can cause developmental toxicity according to state or federal government labeling requirements.
2068-78-2Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Antimitotic Agents
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Danger
H300 (91.5%): Fatal if swallowed [Danger Acute toxicity, oral]
P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 47 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
SYMPTOMS: The following symptoms of exposure have occurred during intravenous use. Symptoms of exposure include bone marrow depression, peripheral neuropathy, colicky abdominal pain, constipation and alopecia. Other symptoms include neuromuscular and neurological disturbances, gastrointestinal upset and leucopenia. It has caused impaired walking, convulsions, hypertension, inappropriate antidiuretic hormone (ADH) secretion, jaw pain, paresthesias in the fingers and toes, sensory impairment, headache, loss of deep tendon reflexes, parotid gland pain, optic atrophy and blindness. It has also caused acute uric acid nephropathy, myocardial infarction, ocular toxicity (ptosis, other ocular muscle paresis, and 5th and 7th nerve involvement); laryngeal nerve paralysis causing hoarseness or cough, depression of the Achilles tendon reflex, muscle pain, weakness, motor weakness, quadriparesis, numbness and tingling of the fingers and toes, malaise, depression, psychoses, neuromyopathy, peripheral neuritis, adynamic ileus, and permanent central nervous system damage. Exposure may cause paresthesia, foot drop, ataxia, athetosis, thrombocytosis and coma. Exposure may also cause granulocytopenia, thrombocytopenia, hypoplasia of all elements of bone marrow, nausea, vomiting, anorexia, neuritic pain and motor difficulties. Other effects may include cranial nerve neuropathy including optic nerve neuropathy and injury to the retina; cataracts, facial paralysis, diplopia and corneal hypesthesia. It may cause anemia, polyuria, dysuria, fever, tingling and numbness of the extremities, abdominal obstruction, ischemic cardiac toxicity and syndrome of hyponatremia. It may also cause diarrhea, sensory loss, slapping gait, muscle wasting, generalized sensorimotor dysfunction, paralytic ileus, abdominal cramps, rash, oral ulceration, intestinal necrosis and/or perforation, urinary retention due to bladder atony cranial nerve manifestations including isolated paresis and/or paralysis of muscles controlled by cranial motor nerves; pharyngeal pain, bone pain, back pain, limb pain, myalgias, renal or adrenal disease, hypotension, dehydration, azotemia and clinical edema. Effects on the autonomic nervous system have been reported. It may cause irritation of the skin, and congenital malformation in the fetus.
Hepatic. Cytochrome P450 isoenzymes of the CYP3A subfamily facilitate the metabolism of vincristine. Route of Elimination: The liver is the major excretory organ in humans and animals. 80% of an injected dose of vincristine sulfate is excreted via feces. 10 - 20% is excreted via urine. Half Life: When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.
VINCRISTINE SULFATE
Vinca Alkaloids [CS]; Vinca Alkaloid [EPC]
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
용도Vincristine sulfate, is used as an anticancer agent, microtubule disrupter, Induces apoptosis in human lymphoma cells. Other applications include as a cell cycle arresting, apoptotic inducing alkaloid.
일반 설명Vincristine sulfate appears as an anticancer drug. White to slightly yellow, amorphous or crystalline powder. Sensitive to light. Odorless. pH (0.1% solution) 3.5 - 4.5. (NTP, 1992)
DTXSID8044331CHEMBL501867Crystalline Solid
EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.
SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.
RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)
The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca<sup>2+</sup>-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.
Vincristine sulfate
Group 3: Not classifiable as to its carcinogenicity to humans
Volume 26: (1981) Some Antineoplastic and Immunosuppressive Agents
1987
1987
Vincristine sulfate is not classifiable as to its carcinogenicity to humans (Group 3). Vincristine is part of MOPP, a combination chemotherapy regimen that is carcinogenic to humans (Group 1). (L135)
Drug Induced Liver Injury Rank (DILIrank 2.0)
Vincristine sulfate
vLess-DILI-concern
8
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015